Current Report Filing (8-k)
July 15 2021 - 4:32PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities and Exchange Act of 1934
Date
of Report (Date of earliest event reported): July 15, 2021
LifeMD,
INC.
(Exact
name of Registrant as specified in its charter)
Delaware
|
|
001-39785
|
|
76-0238453
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
800
Third Avenue, Suite 2800
New
York, NY 10022
(Address
of principal executive offices, including zip code)
(866)
351-5907
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any
of the following provisions:
[ ]
|
Written
communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, par value $0.01 per share
|
|
LFMD
|
|
The
Nasdaq Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
8.01 Other Events.
On
July 15, 2021, LifeMD, Inc. (the “Company”) issued a press release announcing its collaboration with the world’s leading
provider of laboratory diagnostic services and a technology leader in in-home healthcare to deliver telehealth access to diagnostic laboratory
testing services. Specifically, the Company, on behalf of its customers, has engaged Quest Diagnostics Incorporated (“Quest Diagnostics”)
as the Company’s laboratory services provider to perform certain clinical laboratory diagnostic services based on orders submitted
to Quest Diagnostics by licensed health care providers who are under contract with the Company and are authorized under U.S. federal
or state law to order laboratory tests. Patients of LifeMD’s affiliated providers gain access to more than 150 of the most ordered
laboratory tests at substantially discounted prices, and which can be completed in the comfort, safety, and convenience of their home
or office. In addition, the Company has engaged Axle Health Inc. (“Axle Health”) to assist the Company in establishing a
platform to enable patients of the Company’s medical practice clients (“MP Clients”) to schedule certain nursing services,
including blood draws, injections, and other basic healthcare services, and to furnish operational support services to medical practices
using the platform. In connection therewith, Axle Health granted the Company a revocable, nontransferable, non-exclusive right and license,
with the right to grant sublicenses, to install and use the software and other technology relating to the platform developed, owned,
or with the right to grant sublicenses to install and use the software and/or other technology developed, owned, or licensed
by Axle Health, including the platform, to facilitate the scheduling and provision of certain nursing services to patients of MP Clients.
A copy of the press release is filed hereto as Exhibit 99.1 and is incorporated herein by reference.
Item
9.01. Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
LifeMD,
INC.
|
|
|
|
|
Dated:
|
July
15, 2021
|
By:
|
/s/
Justin Schreiber
|
|
|
|
Justin
Schreiber
Chief Executive Officer
|
LifeMD (NASDAQ:LFMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
LifeMD (NASDAQ:LFMD)
Historical Stock Chart
From Sep 2023 to Sep 2024